Released by Arcview Market Research and BDS Analytics, the Pharmacies vs. Dispensaries: The Future of Cannabinoids as Medicine report details the many ways in which the cannabis industry could potentially disrupt the pharmaceutical industry. The report explains that the pharmaceutical industry stands to be changed by the popularization of cannabis in two ways: the emergence of cannabis-derived pharmaceutical drugs, and the possible competition between pharmacies and dispensaries as customers begin to trust cannabis to alleviate health issues.
The report indicates that cannabinoid pharmaceutical sales are unlikely to take off in the near term, as only five cannabinoid-based pharmaceuticals are in third-stage trials, and therefore have a chance of getting through the FDA approval process and onto the market before 2022. Hence sales of all cannabis-based pharmaceuticals are forecast to amount to less than 20% of the $31.6-billion legal cannabis market by 2022.
Other key factors analyzed in the report include:
The 57-page report is available for $297 or as part of the Cannabis Intelligence Briefing Series subscription service from Arcview Market Research and BDS Analytics for $1,975.